LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotech firm focused on Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has received a notice of allowance from the Canadian Intellectual Property Office for a patent related to inflammatory condition treatments. The patent, expected to be issued soon, pertains to methods for modulating type 2 and/or type 1 invariant NKT cells, specifically in the liver, using a Retinoic Acid Receptor agonist.
This development is part of the company's broader efforts to protect its intellectual property as it advances its drug pipeline. GRI Bio's lead candidate, GRI-0621, is currently in a Phase 2a study targeting Idiopathic Pulmonary Fibrosis (IPF), a rare lung disease. Interim results from this study are anticipated in the first half of 2024, with final data expected later in the year.
GRI-0621 is a small molecule dual agonist designed to inhibit the activity of human iNKT cells and is being developed as an oral therapeutic. Beyond IPF, GRI Bio is also working on type 2 NKT agonists for systemic lupus erythematosus treatment and has a library of over 500 proprietary compounds to fuel its pipeline.
The notice of allowance is a crucial step in securing patent rights that CEO Marc Hertz believes underscores the company's differentiated approach to treating diseases with significant unmet needs.
This article is based on a press release statement from GRI Bio, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.